Clin2
NCT07161193Possibly a fitNot yet recruiting

CAR T-cell therapy for hard-to-treat autoimmune diseases

Autoimmune Diseases

Treatments studied

Part of Immune system & allergy clinical trials.

This trial tests a type of immune cell therapy called CAR T-cells that target CD19, for people with severe autoimmune diseases that haven't improved with standard treatments. The goal is to see if it can help calm the immune system and reduce disease activity.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
30 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have been diagnosed with one of these conditions for at least 6 months: lupus, myositis, scleroderma, pemphigus, psoriasis, rheumatoid arthritis, or ANCA vasculitis.
  • Your disease is moderate to severe and has not responded well to at least 12 weeks of standard therapy.
  • You must use effective birth control if you could become pregnant (women need a negative pregnancy test).
  • You are able to provide medical records from the last 3 months and agree to follow the study schedule.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06688799Recruiting· Phase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases

This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.

Beijing, Beijing Municipality
NCT06680388Recruiting· Early Phase 1
CD19 CAR-T for severe autoimmune diseases

This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.

Tianjin, Tianjin Municipality
NCT06350110Recruiting· Phase 1/Phase 2
CAR T cells for lupus

This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.

Beijing, Beijing Municipality
NCT06056921Recruiting· Phase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases

This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.

Taiyuan, Shanxi
NCT06349343Recruiting· Phase 1
CAR-T cell therapy for hard-to-treat lupus

This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.

Wuhan
NCT06685042Recruiting· Phase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases

This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.

Rome, Lazio

Hear when a new Autoimmune Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.